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Aortic stenosis severity has no influence  
on automatically measured standard platelet parameters  
— other cardiovascular risk factors play crucial role
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Abstract
Introduction. Calcification of the aortic valve, the main component of degenerative aortic stenosis (AS), results in turbu-
lent blood flow, higher shear stress and may have an effect on the platelet (PLT) parameters. Platelet function and size, 
which are easily measured automatically during a complete blood count, are proposed as markers of platelet reactivity 
and risk factors for cardiovascular diseases.
Material and methods. 143 patients with AS (mean age: 70 ± 13 y., males 76/53%) were enrolled into the study and 
divided according to the AS severity: severe AS (n = 89; males 43/48.3%; age IQR: 70 [63–75] y.) and non-severe AS 
(n = 54; males 63/61.1%; age IQR: 70 [62–76] y.). The clinical data were collected and analyzed with special attention 
being paid to the cardiovascular risk factors, concomitant diseases (coronary artery disease [CAD], diabetes mellitus, 
arterial hypertension, obesity). Laboratory tests and echocardiography were assessed in all subjects. Routine admis-
sion complete blood cell count was obtained — PLT count, mean PLT volume (MPV), PLT distribution width (PDW) and 
percentage of giant PLT (giant PLT%) were analyzed.
Results. There were no differences between the PLT count, MPV, PDW and giant PLT% when comparing the group with 
severe AS to the non-severe AS group. Multivariate analysis showed a significant effect of CAD coincidence (β = –0.2, 
SE = 0.09, p = 0,03) and active smoking (β = –0.2, SE = 0.09, p = 0.03) on the PLT count; obesity (β = 0.2, SE = 0.09, 
p = 0.03) and CAD (β = –0.2, SE = 0.09, p = 0.03) on MPV; obesity (β = 0.21, SE = 0.09, p = 0.02), thienopyridines 
(β = 0.19, SE = 0.09, p = 0.03) and LMWH intake (β = 0.21, SE = 0.09, p = 0.02) on PDW; and similarly, obesity 
(β = 0.23, SE = 0.09, p = 0.01), thienopyridines (β = 0.18, SE = 0.09, p = 0.046) and LMWH intake (β = 0.23, SE = 0.09, 
p = 0.01) on giant PLT%.
Conclusions. Aortic stenosis severity has no effect on PLT count and morphology that are automatically measured. The 
coincidence of standard cardiovascular risk factors and the CAD effects on the PLT parameters that are established 
during a standard complete blood count.
Key words: aortic stenosis, platelet parameters, platelet count, platelet distribution width, percentage of giant platelets, 
mean platelet volume
(Folia Cardiologica 2015; 10, 5: 315–321)
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Introduction
Platelets originate in the bone marrow during megakary-
opoiesis and are constantly released into the bloodstream. 
Morphologically, they are devoid of nuclei cells that are 
filled with granules of vasoactive and prothrombotic factors 
(including thromboxane A2, serotonin and ATP). While circu-
lating in the blood, platelets may differ, not only in number, 
shape or size, but also in their potential to maintain the 
continuity of the vascular system through complex hemo-
static functions, which are regulated by agonists such as 
ADP, collagen or epinephrine. Their activation causes an 
increased expression of platelet membrane adhesive mole-
cules such as P-selectin, GP Ib and IIb/IIIa receptors [1–3].
Calcification of the aortic valve, which is the main com-
ponent of degenerative aortic stenosis (AS), is connected 
with alterations in shape and the valve orifice, which results 
in a turbulent blood flow, higher shear stress and may 
finally have an effect on the platelet parameters. The mor-
phological platelet parameters, which are easily measured 
automatically during a routine complete blood count, are 
proposed as markers of platelet reactivity and also as risk 
factors for cardiovascular diseases.
The sudden and abrupt changes in the direction of 
blood flow, which occur in AS, are connected with the 
activation of platelets, hence they induce an increased ten-
dency to form blood clots (as a result of atherothrombotic 
disease). Peripheral thrombosis is one of the major compli-
cations that is associated with aortic valve stenosis [4, 5].
The greater volume of platelets that is observed in 
patients with AS is associated with the increased meta-
bolic and enzymatic activity of platelets, and this fact is 
supported by the literature [6]. However, there is still a lack 
of reliable, evidence-based scientific reports that analyze 
all of the platelet parameters in patients with aortic ste-
nosis, who are often burdened with both cardiovascular 
risk factors as well as with coronary heart disease itself. 
The assessment of platelet parameters remains an under-
valued test in routine clinical practice in spite of the wide 
availability and low assay cost possibly due to the difficulties 
with their full and comprehensive interpretation. The aim 
of the study was to assess the affect of AS severity on the 
PLT count and morphology and to observe whether other 
clinical factors play important roles in determining the PLT 
parameters in patients with AS.
Material and methods
One hundred and forty-three patients with newly or previou-
sly diagnosed AS who were hospitalized in the Department 
of Cardiology between 2007 and 2011 were enrolled into 
the study (mean age: 70 ± 13 y., males 76/53%). The study 
population was divided into two groups: 1) group 1: patients 
with severe aortic stenosis (n = 89, males 43/48.3%, age 
IQR: 70 [63–75] years); 2) group 2: patients with non-
-severe (mild and moderate) aortic stenosis (n = 54, males 
63/61.1%, age IQR, 70 [62–76] years).
All of the necessary clinical data were assessed in all 
subjects on admission: determination of any concomitant 
diseases, as well as a physical examination, laboratory 
tests and echocardiography were performed. The routine 
complete blood count on admission was obtained with 
special attention being paid to the platelet parameters.
The standard exclusion criteria that are used in our lab 
include: a history of liver disease, paraproteinemia, mye-
loproliferative disorders, myelodysplastic syndrome, end 
stage renal failure (GFR < 15 ml/min/1,73 m2), previously 
diagnosed antiplatelet antibodies, disseminated intravas-
cular coagulation, having undergone cardiopulmonary 
bypass (in the preceding one month), acute infection, drug 
intake before hospitalization: nonsteroidal anti-inflamma-
tory drugs (except aspirin), beta-lactam antibiotics, GP IIb/ 
/IIIa receptor antagonists, psychotropic drugs and herbal 
supplements.
Informed consent was obtained from each patient. The 
study protocol was approved by the Bioethics Committee of 
the Medical University of Silesia and performed according 
to the ethical guidelines of the 1975 Declaration of Helsinki.
Clinical data
A detailed medical history was collected from each sub-
ject that included: the current course of the disease, the 
main symptoms (classified in NYHA and CCA class), any 
concomitant diseases (including coronary artery disease 
[CAD], diabetes type 2 [DM], arterial hypertension [HA], 
hyperlipidaemia), family history, precise pharmacotherapy 
(especially aspirin, thienopyridines, low molecular weight 
heparins), alcohol and coffee intake and active tobacco 
smoking. We also collected physical examination parame-
ters including: weight, height, body mass index (BMI), body 
surface area (BSA) and arterial blood pressure.
Coronary artery disease
In the study we included patients with a history of acute 
coronary syndrome and/or atherosclerosis of coronary 
vessels that was confirmed by coronary angiography.
Diabetes type 2
Patients with diagnosed diabetes (new or prior to hospita-
lization) were taken into consideration.
Obesity
Obesity was defined as BMI ≥ 30 kg/m2.
Active smoking
Patients who continue to smoke cigarettes.
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Arterial hypertension
Arterial hypertension that was diagnosed prior to or during 
hospitalization was based on the 2007 guidelines for the Ma-
nagement of Arterial Hypertension of the European Society of 
Hypertension and of the European Society of Cardiology [7].
Laboratory tests
Blood for the laboratory tests was collected from a pe-
ripheral vein using EDTA preservative (disodium edetate) 
between 6:00 and 8:00 a.m. after at least an eight-hour 
fast. The blood samples were delivered to the laboratory 
where tests were performed using a Sysmex SF-3000 ap-
paratus within 30 minutes. The time from the receipt of the 
blood to the final tests did not exceed more than one hour 
in order to avoid any effect of the EDTA preservative on the 
platelet parameters. We routinely evaluated the following 
parameters: total blood platelet count (PLT count), mean 
platelet volume (MPV), platelet distribution width (PDW) and 
percentage of giant platelets (giant PLT%). Thrombocytope-
nia was defined as a PLT count < 150 × 103/ml.
Echocardiography
On admission, ECG-gated transthoracic echocardiography 
was performed in all patients, and in some cases trans-
esophageal echocardiography, in order to visualize the 
aortic valve more accurately.
An experienced physician took all of the measurements 
using the same investigation protocol and techniques in or-
der to reduce inter- and intra-observer variability in accord-
ance with the European Society of Cardiology guidelines, 
especially the European Association of Echocardiography/ 
/American Society of Echocardiography recommendations 
on the echocardiographic assessment of valve stenosis [8].
In order to assess the severity of AS the following para-
meters were assessed: maximal (Pmax) and mean (Pmean) 
transvalvular pressure gradients, maximal blood velocity 
(Vmax), aortic valve area (AVA) using planimetry, which were 
then indexed depending on BSA. Patients with severe aortic 
stenosis were classified according to the European Society 
of Cardiology guidelines on the treatment of valvular heart 
disease (version 2012) [9].
The AS severity was established according to combina-
tion of following parameters with cut-off values:
 — AVA < 1 cm2 (most likely when < 0.8 cm2);
 — AVA/BSA < 0.6 cm2 (preferred in patients with small 
BSA);
 — transvalvular Vmax > 4 m/s;
 — transvalvular Pmean > 40 mm Hg.
The parameters of left ventricular (LV) geometry and 
function, as well as the function of other valves were col-
lected using the two-dimensional left parasternal long-axis 
view: LV end-diastolic and end-systolic volume, LV ejection 
fraction, stroke volume, stroke volume index, interventricu-
lar septum, LV mass and left ventricular mass index. The 
investigation was performed using Toshiba Aplio equipment 
with a 2.5 MHz sector ultrasound transducer and 2–7 MHz 
transesophageal transducer.
Statistical analysis
Statistical analysis was performed using STATISTICA for 
Windows (a data analysis software system). All data was 
collected in a Microsoft Office Excel spreadsheet. The 
U-Mann-Whitney test was used to compare two non-normally 
distributed variables, while the t-Student or Cochran-Cox 
tests were used for the comparison of normally distributed 
continuous variables when the variances were not homoge-
neous as tested using the Levene test. A p value of less than 
0.05 was considered to indicate statistical significance.
The distribution of variables was tested using the Shapiro- 
-Wilk test and continuous variables are reported as the 
mean with the standard deviation or the median with the 
interquartile range (25–75 Q) for non-normal distributions, 
while categorical variables are reported as absolute num-
bers and percentages.
Stepwise multivariate analysis was performed with 
platelets parameters and concomitant diseases, aortic 
stenosis degree, addictions and drugs as the dependent 
variables. The following variables were included: age, 
gender, concomitant diseases/risk factors such as obesity, 
CAD, HA, DM, current smoking, severe AS presence, aspirin, 
thienopyridines and low molecular weight heparin intake.
Results
Clinical characteristic
Demographic data, initial clinical assessment, concomitant 
diseases/risk factors, drugs, platelet and erythrocyte para-
meters, as well as the echocardiographic data that charac-
terized both groups are included in Tables 1, 2 and 3. The 
analyzed groups were statistically similar according to age, 
gender, BSA, BMI, LV ejection fraction, systolic and diastolic 
blood pressure, frequency of antiplatelet and antiaggregant 
drug intake. Concomitant diseases/risk factors (HA, DM, 
CAD, smoking and obesity) were reported equally frequently 
in both groups, regardless of the degree of aortic stenosis.
Depending on the severity of AS, PLT count, MPV, PDW 
and giant PLT% were statistically similar when comparing 
group with severe AS to the non-severe AS group. Active 
smoking was connected with a decreased PLT count (med-
ian [IQR]: 126.5 [115–133] vs 164 [135–197], p < 0.001) 
and more frequent thrombocytopenia (n/%: 10/100% vs 
47/36.4%, p < 0.001) compared to that of non-smokers. 
Obese patients had a statistically higher giant PLT% (mean 
± SD: 35.5 ± 5.8 vs 31.8 ± 8.1, p = 0.004), PDW (median 
[IQR]: 13.7 [12.8–15.3] vs 12.6 [11.8–14.6], p = 0.002) 
and MPV (median [IQR]: 11.4 [10.7–11.8] vs 10.6 [10.1– 
–11.3], p = 0.002) than non-obese subjects; similarly, 
the coincidence of DM was associated with a significantly 
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Table 1. Clinical characteristic of groups
Severe AS 
n = 89
Non-severe AS 
n = 54
Measure p value
Age, years 70 (63–75) 70 (62–76) med. (IQR) 1
Male gender 43/48.3% 33/61.1% n/% 0.1
Weight [kg] 79.4 ± 13.3 
51–115
80.4 ± 12.8 
55–114
mean ± SD 
min–max
0.68
Height [m2] 166.2 ± 8.8 
145–185
167.4 ± 8.3 
149–184
mean ± SD 
min–max
0.44
BMI [kg/m2] 28.6 ± 4.1 
18.5–40
28.7 ± 4.5 
19.8–44.5
mean ± SD 
min–max
0.89
BSA [m2] 1.9 ± 0.2 
1.5–2.4
1.9 ± 0.2 
1.5–2.4
mean ± SD 
min–max
0.61
AVA [cm2] 0.7 (0.57–0.87) 1.35 (1.0–1.6) med. (IQR) < 0.001
AVA plan. [m2] 0.8 ± 0.3 
0.2–1.5
1.3 ± 0.3 
0.8–2.0
mean ± SD 
min–max
< 0.001
AVA/BSA [cm2/m2] 0.34 (0.28–0,46) 0.65 (0,50–0,84) med. (IQR) < 0.001
Vmax [m2] 4.5 ± 0.8 
2.2–6.8
3.1 ± 0.6 
1.7–4.3
mean ± SD 
min–max
< 0.001
Pmax [mm Hg] 83 ± 29.2 
19–180
40.4 ± 14.7 
10.7–76
mean ± SD 
min–max
< 0.001
Pmean [mm Hg] 49 (37–60) 23.5 (16–27) med. (IQR) < 0.001
LVEF [%] 58 (48–63) 60 (53–67) med. (IQR) 0.12
SBP [mm Hg] 129.4 ± 18.3 
92–170
129.1 ± 15.7 
100–150
mean ± SD 
min–max
0.95
DBP [mm Hg] 80 (72.5–80) 80 (70–85) med. (IQR) 0.78
n — number; AS — aortic stenosis; med. — median; IQR — interquartile range; SD — standard deviation; ; min–max — minimal-maximal range; BMI — body mass index; BSA — body surface area; AVA — aortic 
valve area; AVA plan. — planimetric aortic valve area; AVA/BSA — indexed aortic valve area; Vmax — maximal blood velocity; Pmean — maximum and transvalvular pressure gradient; Pmax — maximum 
transvalvular pressure gradient; LVEF — left ventricular ejection fraction; SBP — systolic blood pressure; DBP — diastolic blood pressure
Table 2. Characteristic of groups depending on type of taken drug and concomitant disease/risk factor
Severe AS 
n = 89
Non-severe AS 
n = 54
Measure p value
Obesity 29/36.5% 19/35.9% n/% 1
Coronary artery disease 52/58.4% 29/53.7% n/% 0.6
Hypertension 67/75.3% 47/87% n/% 0.09
Diabetes type 2 23/25.8% 13/24% n/% 0.8
Smoking 5/5.6% 5/9.6% n/% 0.5
ASA 74/87% 47/87% n/% 1
Thienopyridines 7/8.3% 10/18.5% n/% 0.07
LMWH 10/11.8% 4/7.4% n /% 0.4
AS — aortic stenosis; n — number; ASA — acetylsalicylic acid intake; LMWH — low molecular weight heparin intake
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increased giant PLT% (mean ± SD: 35.5 ± 6.7 vs 32.4 ± 
± 7.7, p = 0.03) and PDW (median [IQR]: 13.6 [12.6–15.9] 
vs 12.9 [11.9–14.7], p = 0.04). Patients with AS and CAD 
had a decreased PLT count (median [IQR]: 144 [129–180] 
vs 170 [151–203], p = 0.003) with a higher prevalence of 
thrombocytopenia (n/%: 43/53% vs 15/25%, p < 0.001) 
and increased MPV (median [IQR]: 11.1 [10.4–11.9] vs 
10.6 [10.2–11.1], p = 0.02) and giant PLT% (median [IQR]: 
34.5 [28.7–39.7] vs 30.8 [27.1–34.8], p = 0.02). The 
coincidence of HA has no impact on platelets parameters.
Multivariate analysis
Multivariate analysis showed a significant affect of CAD 
coincidence (β = –0.2, SE = 0.09, p = 0.03) and active 
smoking (β = –0.2, SE = 0.09, p = 0.03) on the PLT count; 
obesity (β = 0.2, SE = 0.09, p = 0.03) and CAD (β = –0.2, 
SE = 0.09, p = 0.03) on MPV; obesity (β = 0.21, SE = 0.09, 
p = 0.02), thienopyridines (β = 0.19, SE = 0.09, p = 0.03) 
and LMWH intake (β = 0.21, SE= 0.09, p = 0.02) on PDW, 
and similarly, obesity (β = 0.23, SE = 0.09, p = 0.01), thie-
nopyridines (β = 0.18, SE = 0.09, p = 0.046) and LMWH 
intake (β = 0.23, SE = 0.09, p = 0.01) on giant PLT%. We 
found only trend to significance when analyzing the impact 
of diabetes mellitus on the giant PLT% (β = 0.15, SE = 0.08, 
p = 0.07), with no impact on the other parameters.
Discussion
The paper is one the first on broad analyses of platelet 
characteristics in aortic stenosis depending on its severity 
and cardiovascular comorbidities. No affect on the analyzed 
parameter was observed when the entire group with a ste-
notic aortic valve was assessed, MPV, PLT count, giant PLT% 
and PDW did not differ. The analyzed group, regardless of 
aortic stenosis severity, severe or non-severe, was homo-
Table 3. Characteristic of groups depending on laboratory tests
Severe AS 
n = 89
Non-severe AS 
n = 54
Measure p value
Leukocytes [× 10³/µl] 6.6 (5.8–8.1) 6.3 (5.5–7.7) med. (IQR) 0.26
Erythrocytes [× 10³/ml] 4.5 (4.3–4.8) 4.4 (4.1–4.8) med. (IQR) 0.4
Hb [g/dl] 13.5 ± 1.5 
9–16.5
13.5 ± 1.6 
9.5–17.2
mean ± SD 
min–max
0.94
Ht [%] 41 (37.8–43.4) 40.1 (37.6–42.7) med. (IQR) 0.56
PLT [× 10³/µl] 160 (132–188) 163 (129–201) med. (IQR) 0.9
Thrombocytopenia 36/41.4% 22/40.8% n/% 0.94
PDW [fl] 13.3 (12.3–15.3) 12.6 (12.1–14) med. (IQR) 0.1
MPV [fl] 11.1 (10.4–11.8) 10.6 (10.3–11.4) med. (IQR) 0.1
Giant PLT% [%] 33.8 ± 8 
17.8–57.6
32.1 ± 6.8 
20–49.8
mean ± SD 
min–max
0.3
n — number; AS — aortic stenosis; med. — median; IQR — interquartile range; Hb — hemoglobin; SD — standard deviation; min–max — minimal-maximal range; Ht — hematocrit; PLT — blood platelet count; 
PDW — platelet distribution width; MPV — mean platelet volume; giant PLT% — percentage of giant platelets
geneous as to age, gender, BMI, BSA and any anti-platelet 
agents they were taking. A similar incidence of additional 
analyzed risk factors and cardiovascular diseases such as 
CAD, DM, obesity, smoking and HA was observed.
In the majority of papers that were focused on platelet 
parameters in patients suffering from particular cardiovas-
cular disease without aortic stenosis, a significant affect 
of anti-platelet agents, which can interfere with the an 
accurate measurement of platelet characteristics, thereby 
causing dysfunction in the secondary platelets, was avoided 
[10]. Among the analyzed platelet parameters, a lower PLT 
count in individuals that had been treated with thienopyri-
dines, a greater giant PLT% in those that had been treated 
with thienopyridines as well as patients who had been 
treated with LMWH and a greater PDW count in individuals 
who had been treated with thienopyridines were observed.
The available studies broadly assess platelet cha-
racteristics in patients with acute coronary syndrome in 
comparison with patients without CAD or with stable CAD. 
Greater values of MPV were described [11]. Other papers 
reported a significantly reduced PLT count [12]. A greater 
MPV with a normal PLT count were observed in individuals 
with stable CAD.
In the analyzed patient subpopulation with AS and CAD, 
a greater MPV and lower PLT often resulting in an abnormally 
low PLT count as well as a significantly increased giant PLT% 
were observed. Moreover, diabetes type 2 predisposed 
individuals to a significantly greater giant PLT% and PDW. 
Numerous papers report increased MPV and PDW in individ-
uals with isolated type 2 diabetes [13]. However in analyzed 
population of patients, diabetes type 2 was no significant 
independent parameter influencing on platelets parameters, 
simultaneously this excludes interfering impact of the most 
potent factor on the statistical analysis of other factors. It 
is worth to mention, that performed stepwise multivariate 
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analysis revealed tendency to significant influence of dia-
betes type 2 on giant PLT%.
An increased giant PLT%, MPV and PDW with no affect 
on PLT count in comparison to normal body mass indivi-
duals were observed in obese patients. Papers that ana-
lyze the effect of body mass on platelets report a greater 
MPV in obese patients followed by its normalization after 
weight loss [14].
There is evidence of a greater MPV with subsequent 
decrease in the PLT count with no PDW change in patients 
who smoke. After smoking cessation, MPV and PLT normal-
izes after three months [15]. Due to contradictory reports, 
the effect of smoking on MPV remains unclear [16, 17]. Our 
analysis confirms a significant PLT decrease as a result of 
smoking in patients with AS.
We did not observe any significant affect of HA coinci-
dence on the variability of platelet characteristics. Available 
data regarding an isolated HA effect is inconsistent — some 
papers deny that one exists [1], while others describe it 
as significant [18].
Platelet size may be correlated with their activation and 
escalated function. Increased MPV was described in disea-
ses such as type 2 diabetes, hypercholesterolemia, obesity, 
AMI, ischaemic stroke, metabolic syndrome, preeclampsia 
or renal artery stenosis, which that are known to be risk 
factors, or as a result of atherosclerosis [1, 19].
It is worth mentioning that MPV is known to be an 
adverse prognostic factor for MI, coronary stent resteno-
sis, as well as preeclampsia. There are also numerous 
rationales that suggest that MPV may be treated as an 
independent risk factor of cardiovascular diseases [1, 19]. 
A greater MPV is correlated with increased platelet activity 
and a decreased bleeding time [4, 19]. New parameters 
are actively being researched. PDW has recently been 
postulated to be a more specific platelet activity marker. 
The change in shape from disk to sphere with subsequent 
pseudopodia formation from a cell membrane probably 
takes place during platelet activation, which results in 
a change in PDW [20].
It is worth to mention that high percentage of patient 
taking aspirin resulted from extended indications, accord-
ing to guidelines valid in year 2004 [21].
Basic platelet characteristics appear to be genetically 
regulated during megakaryopoiesis [22]. Reactivity, activa-
tion state and finally inter-individual variability in healthy 
subjects can disrupt measurements and proper deduction. 
In clinical practice, repeated measurements and assess-
ments of all of the available platelet parameters may result 
in better knowledge about the function and activation of 
platelets.
Limitations of the study
The wide range of platelet parameter values that can be 
observed in the literature may be caused by the factors 
that are listed or the dysfunction of platelets [10] as well as 
a lack of a proper laboratory measurement standardization 
[23, 24]. The risk factors were not isolated in the analyzed 
group. Many factors, which appear to have key roles, are 
correlated as risk factors and the result of atherosclerosis.
Conclusions
1. In patients with AS, the severity of stenosis has no affect 
on the platelet count and morphology. 2. The coincidence of 
standard cardiovascular risk factors and the CAD in patients 
with AS effects on the PLT parameters that are established 
during a standard complete blood count.
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Streszczenie
Wstęp. Kalcyfikacje zastawki aortalnej, będące głównym komponentem degeneracyjnego zwężenia zastawki aortalnej 
(AS), skutkują turbulentnym przepływem krwi, co z kolei może wpływać na parametry płytek krwi (PLT). Funkcja i wielkość 
PLT, łatwo oznaczane podczas rutynowej morfologii krwi obwodowej, mogą być markerami aktywności PLT i potencjal-
nymi czynnikami ryzyka chorób układu sercowo-naczyniowego.
Materiał i metody. Do badania włączono 143 pacjentów z AS (średni wiek: 70 ± 13 l., mężczyźni 76/53%) i podzielono 
na dwie podgrupy zależnie od ciężkości AS — z ciężką AS (mediana wieku: 70 [63–75] l., n = 89, mężczyźni 43/48,3%) 
oraz nieciężką AS (mediana wieku: 70 [62–76] l., n = 54, mężczyźni 63/61,1%). U wszystkich chorych wykonano 
przezklatkowe badanie echokardiograficzne oraz zebrano wywiad lekarski, ze szczególnym uwzględnieniem czynników 
ryzyka chorób układu sercowo-naczyniowego i schorzeń współistniejących (choroby wieńcowej [CAD], cukrzycy typu 2, 
nadciśnienia tętniczego, otyłości, palenia tytoniu). W wykonanej rutynowo morfologii krwi obwodowej analizie poddano 
następujące parametry płytkowe: liczbę płytek (PLT count), średnią objętość płytek (MPV), wskaźnik anizocytozy płytek 
(PDW), odsetek płytek olbrzymich (giant PLT%).
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